NANETS produces a monthly eNewsletter, Net News. Net News contains information on recent NET disease research, guidelines and resources. It also highlights NET continuing medical education (CME) programming, medical society developments, member accomplishments and news from other NET organizations. Have news to share? Contact us! Net News is a benefit of membership in NANETS. Not a member? Subscribe now!


The North American Neuroendocrine Tumor Society was established in 2007 with the mission of furthering neuroendocrine tumor disease diagnosis, treatment and management. Since its inception, NANETS has remained dedicated to this mission through the provision of increased education and research opportunities. It is through research grants NANETS engages medical professionals in the early part of their careers to foster further exploration and advancement of NET diagnosis and treatment.

Since 2009, NANETS has awarded $1.5 million in research grants to 22 medical professionals. This year, NANETS is pleased to offer three research grants to support innovative research initiatives and encourage young researchers and scientific clinicians to become NET specialists.

NANETS Basic/Translational Science Investigator (BTSI)

The NANETS Basic/Translational Science Investigator (BTSI) is awarded to scientists at the end of their fellowship or in the beginning of their faculty appointment, who are predominantly focused on lab-based, basic/translational research. The BTSI is intended to encourage the scientific inquiry in the field of basic/translational science as it relates to NETs. Learn more and submit an application.

NANETS Clinical Investigator Scholarship (NCIS)

The NANETS Clinical Investigator Scholarship (NCIS) encourages clinicians at the end of their fellowship or beginning of their faculty appointment to pursue a clinical career focused on neuroendocrine tumors. The NCIS emphasizes both the professional development of the scientific clinician (whose time is primarily dedicated to patient care) and the potential of the project to directly impact NET patients. Learn more and submit an application.

NANETS Theranostics Investigator Grant (NTIG)

The NANETS Theranostics Investigator Grant (NTIG) encourages early career professionals to pursue research focused in theranostics and neuroendocrine tumors. This grant will further the exploration of theranostics and its potential to improve the diagnosis and management of neuroendocrine tumors. Given the recent and substantial advances in the area of nuclear theranostics in particular, there is an urgent need to support more of the high-quality research proposals that we receive in this field.  Learn more and submit an application.

               New online grant submission system this year

NANETS is using an online system for the submission of applications. The submission period begins April 1, 2020 through June 12, 2020. The new system allows for editing submissions until the June 12 deadline. Visit our Research Grants Page for more information and to submit an application. For questions, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..

Abstracts are now being accepted for NANETS 2020 Multidisciplinary NET Disease Symposium, October 1-3 in Montreal, Quebec, Canada. 

NANETS' Annual Multidisciplinary NET Medical Symposium represents an excellent opportunity to present research relevant to cutting edge topics in neuroendocrine tumor research. Medical researchers at institutions in North America and around the world are invited to submit. The deadline for submitting abstracts is 11:59 pm Pacific Time, June 12, 2020.

Click here for full instructions and to submit an abstract. 

The Journal of Nuclear Medicine has published the NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radio-nuclide Therapy.

The consensus statement is the result of a collaborative effort between the North American Neuroendocrine Tumor Society (NANETS) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). This is the second publication as part of that collaboration, and it advances the commitment of both societies to improve NET disease management through increased research and educational opportunities, increase the competencies of nuclear medicine practitioners and promote new advances in the science of nuclear medicine.

Thomas A. Hope, MD, lead author of the statement, is Director of Molecular Therapy for the Molecular Imaging and Therapeutics Clinical Section in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He also serves as co-chair of the Cancer Center’s new Molecular Imaging & Radionuclide Therapy Site Committee.
"The guidelines are the product of a truly collaborative discussion, bringing together an even balance of nuclear and medical oncologists to educate communities about the proper way to administer PRRT."

Jonathan R. Strosberg, MD, senior author of the guidelines, is a professor at Moffitt Cancer Center and head of the neuroendocrine tumor division.

"The first guidelines focused on HOW to perform PRRT, while this most recent publication dealt with WHO to treat: identifying where treatment is indicated and where it is contraindicated."
While PRRT is still a relatively new treatment in North America, it is being rolled out in many institutions.

"There are a lot of questions about the appropriate standard of care, and this is not a simple treatment to administer. The guidelines answer questions about how to set up a program and who are the most appropriate patients to receive treatment. There is also an 'appropriateness' scale and a discussion of where treatment is contraindicated."
Other contributing authors of the guidelines are: Lisa Bodei, MD, PhD; Jennifer A. Chan, MD, MPH; Ghassan El-Haddad, MD; Nicholas Fidelman, MD; Pamela L. Kunz, MD; Josh Mailman; Yusuf Menda, MD; David C. Metz, MD; Erik S. Mittra, MD, PhD; Daniel A. Pryma, MD; Diane L. Reidy-Lagunes, MD; and Simron Singh, MD, MPH, FRCPC.